Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

Antisoma plc (~292)

  Print      Mail a friend       Annual reports

Tuesday 01 September, 2009

Antisoma plc

Phase III trial of ASA404 in lung cancer comple...

1 September 2009, London, UK, and Cambridge, MA: Antisoma plc (LSE:
ASM; USOTC: ATSMY) today announces that the ATTRACT-1 phase III trial
of ASA404 in non-small cell lung cancer (NSCLC) has reached its
enrolment target of 1,200 patients. The trial is the single pivotal
registration study for the drug as a first-line treatment for
squamous and non-squamous NSCLC, and is being conducted by Novartis,
Antisoma's development and commercialisation partner for ASA404.

Glyn Edwards, Antisoma's CEO, said: "Novartis has done an excellent
job in rapidly completing recruitment into this very large trial of
ASA404 in lung cancer. We can now be even more confident that the
results will be available in time to support potential marketing
applications in 2011."

Primo N. Lara, Professor of Medicine at the University of California
Davis Cancer Center and U.S. Steering Committee Chair for the
ATTRACT-1 study, said: "Lung cancer afflicts an enormous number of
patients worldwide and there is a clear need for new and improved
treatment options. Phase II trials reported substantial benefits for
lung cancer patients receiving ASA404, and I therefore look forward
greatly to seeing the results of this large and important phase III

ASA404 is a Tumour-Vascular Disrupting Agent (Tumour-VDA) that
selectively disrupts established tumour vasculature, inhibits tumour
blood flow, and causes extensive tumour necrosis.


Daniel Elger, VP Marketing & Communications     +44 (0)7909 915 068
Antisoma plc
Mark Court/Lisa Baderoon/Rebecca Skye Dietrich +44 (0)20 7466 5000
Buchanan Communications
Brian Korb                                     +1 646 378 2923
The Trout Group

Except for the historical information presented, certain matters
discussed in this announcement are forward looking statements that
are subject to a number of risks and uncertainties that could cause
actual results to differ materially from results, performance or
achievements expressed or implied by such statements. These risks and
uncertainties may be associated with product discovery and
development, including statements regarding the company's clinical
development programmes, the expected timing of clinical trials and
regulatory filings. Such statements are based on management's current
expectations, but actual results may differ materially.

About the ATTRACT-1 study
ATTRACT-1 is a pivotal study designed to support applications to
market ASA404 in previously untreated, advanced NSCLC. It is a
randomised, double-blind, placebo-controlled, multicentre phase III
trial being conducted across the US, EU, Japan and other territories.
ATTRACT-1 opened in April 2008 and has enrolled patients with all
histologies, or types, of NSCLC, including squamous and non-squamous
cancers. Patients have been randomised 1:1 to receive either ASA404
plus chemotherapy (carboplatin/paclitaxel) or a placebo plus
chemotherapy (carboplatin/paclitaxel) as a control.

The primary endpoint of ATTRACT-1 is overall survival. Key secondary
endpoints are survival in the squamous and non-squamous patient
subgroups. An interim look is expected to be triggered before the end
of 2009. Following collation and processing of data, the interim look
will take place in early 2010. The outcome will be announced
immediately. The most likely outcome is that the study will continue
to completion. No data will be released unless the look indicates
that the trial should stop because of clear futility or early
evidence of overwhelming efficacy. Full and final data are expected
to be available in late 2010 or early 2011, in time to support
potential applications to market the drug in 2011.

In addition to the ATTRACT-1 trial in previously untreated NSCLC
patients, Novartis is conducting a separate pivotal study, ATTRACT-2,
to evaluate ASA404 in NSCLC patients who have received one previous

About non-small cell lung cancer (NSCLC)
Lung cancer is the biggest cause of cancer death for both men and
women worldwide, with 1.2 million new cases per year and around
920,000 deaths. Around 85-90% of all lung cancer cases are NSCLC.

About ASA404
ASA404 (vadimezan, formerly known as DMXAA and AS1404) is a
small-molecule Tumour-Vascular Disrupting Agent (Tumour-VDA) which
targets the blood vessels that nourish tumours. The drug was
discovered by Professors Bruce Baguley and William Denny and their
teams at the Auckland Cancer Society Research Centre, University of
Auckland, New Zealand. It was in-licensed by Antisoma from Cancer
Research Ventures Limited (now Cancer Research Technology), the
development and commercialisation company of the Cancer Research
Campaign (now Cancer Research UK), in 2001. Worldwide rights to the
drug were licensed to Novartis AG in April 2007; Antisoma has an
option to co-sell ASA404 with Novartis in the United States. Novartis
is conducting phase III studies of ASA404 in NSCLC, and also plans to
investigate the drug's potential as a treatment for metastatic breast

A randomised phase II trial in patients receiving first-line
treatment for NSCLC showed that addition of ASA404 to carboplatin and
paclitaxel chemotherapy improved survival by 5 months. A second,
single-arm, phase II trial also reported positive results with ASA404
in the same patient group.

About Antisoma
Antisoma is a London Stock Exchange-listed biopharmaceutical company
that develops novel products for the treatment of cancer. The Company
has operations in the UK and the US. Please visit for further information about Antisoma.

- END -


This announcement was originally distributed by Hugin. The issuer is 
solely responsible for the content of this announcement.


a d v e r t i s e m e n t